Updated entinostat combo data sinks Syndax shares

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) was off $2.51 (23%) to $8.61 on Thursday after reporting updated response data from the Phase Ib/II ENCORE 601 (KEYNOTE 142) trial of entinostat (SNDX-275) plus PD-1 inhibitor Keytruda pembrolizumab

Read the full 342 word article

User Sign In